cholecalciferol and calcium carbonate
Drugcholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Other names: calcium carbonate
NCT Number: NCT00982722
A randomised double blind clinical trial, accepted by the Medical Products Agency and registered in the European Clinical Trials Database. Aims to evaluate the prevalence of vitamin D deficiency in a pHPT population in relation to gender and age, the correlation between vitamin D status, pre- and postoperative parathyroid hormone level and bone density and the correlation between vitamin D status, metabolic, cardiovascular risk factors and QoL aspects before and after parathyroid adenomectomy.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Karolinska UH, Stockholm, Sweden
150 PHPT patients were randomized six weeks after surgery, 75 into each group, to 1 year of oral treatment with either calcium carbonate 1 g (500 mg twice daily) alone or calcium carbonate 1 g combined with cholecalciferol 1600 IU (800 IU twice daily). Exclusion criteria were age under 18, manifest osteoporosis at PHPTdiagnosis, persistent hypercalcemia after surgery, postoperative hypocalcemia requiring vitamin D treatment, glomerular filtration rate (GFR) below 40 ml/min, pregnancy, breast feeding, or logistical difficulties, for example living far from the hospital. Included patients had to withdraw any current supplementation with calcium and vitamin D during the study period. All tablets were identical in appearance, the tins were numbered and randomization followed a list compiled by an independent clinical research support organization. The time for randomization was chosen to make sure that the PHPT patients were cured before starting the study medication. Nearly three-quarters of the patients were randomized within 6 weeks after PTX.The primary end point was the change in PTH after PTX and treatment with the study medication. Secondary end points were vitamin D levels, insulin resistance, blood pressure and other cardiovascular risk factors, biochemical markers of bone turnover, bone mineral density and self estimated health related quality of life (SF- 36).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Other names: calcium carbonate
calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
Other names: cholecalciferol and calcium carbonate
Time frame: 3 months
PTH
Time frame: one year
24h blood pressure
Time frame: one year
DEXA
Time frame: 3 months
s-25OHD
Time frame: 6 weeks
ionized calcium
Time frame: one year
SF36
Karolinska University Hospital
Other
Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01087619
Arterial Occlusive Diseases, Arteriosclerosis
Lund, Sweden
View Trial DetailsNCT07068867
Endocrine System Diseases, Hyperparathyroidism
Odense, Denmark
View Trial DetailsNCT05022641
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Ann Arbor, Michigan, United States
View Trial DetailsNCT01409798
Calcium Metabolism Disorders, Endocrine System Diseases
Iowa City, Iowa, United States
View Trial Details